Compare Crispr Therapeutics AG (CRSP) vs Toronto-Dominion Bank (TD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Toronto-Dominion Bank — how do they compare? Crispr Therapeutics AG trades at $54.08 (market cap $5.23B), while Toronto-Dominion Bank trades at $121.35 (market cap $200.48B). The key difference: Toronto-Dominion Bank is far larger — about 38.3× Crispr Therapeutics AG's market cap, and Toronto-Dominion Bank pays a 2.63% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | TD | |
|---|---|---|
Market Cap | $5.23B | $200.48B |
Sector | Health | Financials |
52-Week High | $76.78 | $124.80 |
52-Week Low | $44.34 | $72.85 |
Enterprise Value | $3.65B | — |
Dividend Yield | — | 2.63% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Toronto-Dominion Bank
Toronto-Dominion is one of Canada's two largest banks and operates three business segments: Canadian retail banking, U.S. retail banking, and wholesale banking. The bank's U.S. operations span from Maine to Florida, with a strong presence in the Northeast. It also has a 13% ownership stake in Charles Schwab.
Read more on TD →
